Patents by Inventor Yuval Avnir
Yuval Avnir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230132385Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.Type: ApplicationFiled: September 20, 2019Publication date: April 27, 2023Applicants: Tikcro Technologies Ltd., Yeda Research and Development Co. Ltd.Inventors: Ami Navon, Aviv Boim, Ariel Stanhill, Leehee Weinberger, Yuval Avnir
-
Publication number: 20220135655Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.Type: ApplicationFiled: July 26, 2021Publication date: May 5, 2022Inventors: Wayne A. Marasco, Yuval Avnir
-
Publication number: 20210355220Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.Type: ApplicationFiled: September 20, 2019Publication date: November 18, 2021Applicants: Tikcro Technologies Ltd., Yeda Research and Development Co. Ltd.Inventors: Ami Navon, Aviv Boim, Ariel Stanhill, Leehee Weinberger, Yuval Avnir
-
Patent number: 11104722Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.Type: GrantFiled: January 28, 2019Date of Patent: August 31, 2021Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Yuval Avnir
-
Publication number: 20190276519Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.Type: ApplicationFiled: January 28, 2019Publication date: September 12, 2019Inventors: Wayne A. Marasco, Yuval Avnir
-
Patent number: 10179822Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: GrantFiled: November 11, 2016Date of Patent: January 15, 2019Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Publication number: 20170174751Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Inventors: Wayne Marasco, Yuval Avnir
-
Publication number: 20170073431Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: ApplicationFiled: November 11, 2016Publication date: March 16, 2017Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Patent number: 9527924Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: GrantFiled: June 2, 2011Date of Patent: December 27, 2016Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Publication number: 20150093434Abstract: Provided are pharmaceutical compositions including a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.Type: ApplicationFiled: December 4, 2014Publication date: April 2, 2015Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEMInventors: Yechezkel BARENHOLZ, Alberto A. GABIZON, Yuval AVNIR
-
Patent number: 8932627Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.Type: GrantFiled: September 11, 2005Date of Patent: January 13, 2015Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Alberto A. Gabizon, Yuval Avnir
-
Publication number: 20130243749Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: ApplicationFiled: June 2, 2011Publication date: September 19, 2013Applicant: Dana Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Patent number: 7744920Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.Type: GrantFiled: September 11, 2005Date of Patent: June 29, 2010Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew UniversityInventors: Yechezkel Barenholz, Yaakov Naparstek, Yuval Avnir, Rina Ulmansky
-
Publication number: 20080058294Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.Type: ApplicationFiled: September 11, 2005Publication date: March 6, 2008Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Alberto Gabizon, Yuval Avnir
-
Publication number: 20080003276Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.Type: ApplicationFiled: September 11, 2005Publication date: January 3, 2008Inventors: Yechezkel Barenholz, Yaakov Naparstek, Yuval Avnir, Rina Ulmansky